These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 20044209)
41. The cytoprotective effect of amifostine in acute radiation dermatitis: a retrospective analysis. Kouvaris J; Kouloulias V; Kokakis J; Matsopoulos G; Myrsini B; Vlahos L Eur J Dermatol; 2002; 12(5):458-62. PubMed ID: 12370135 [TBL] [Abstract][Full Text] [Related]
42. Chemical radioprotection: a critical review of amifostine as a cytoprotector in radiotherapy. Andreassen CN; Grau C; Lindegaard JC Semin Radiat Oncol; 2003 Jan; 13(1):62-72. PubMed ID: 12520465 [TBL] [Abstract][Full Text] [Related]
43. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma]. Nagy P; Kádasi L Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611 [TBL] [Abstract][Full Text] [Related]
44. Clinical status of the new cytoprotective agent, amifostine. Kalaycioglu M; Bukowski R Oncology (Williston Park); 1994 Jul; 8(7):15-6, 19-20, 23. PubMed ID: 7522504 [TBL] [Abstract][Full Text] [Related]
45. Improving the morbidity of anorectal injury from pelvic radiotherapy. Abbasakoor F; Vaizey CJ; Boulos PB Colorectal Dis; 2006 Jan; 8(1):2-10. PubMed ID: 16519631 [TBL] [Abstract][Full Text] [Related]
46. Current role of protective agents in cancer treatment. Schuchter LM Oncology (Williston Park); 1997 Apr; 11(4):505-12, 515-6; discussion 517-8. PubMed ID: 9130273 [TBL] [Abstract][Full Text] [Related]
47. Radioprotective potential of mint: a brief review. Baliga MS; Rao S J Cancer Res Ther; 2010; 6(3):255-62. PubMed ID: 21119249 [TBL] [Abstract][Full Text] [Related]
56. Combining Pharmacological Countermeasures to Attenuate the Acute Radiation Syndrome-A Concise Review. Hofer M; Hoferová Z; Depeš D; Falk M Molecules; 2017 May; 22(5):. PubMed ID: 28534834 [TBL] [Abstract][Full Text] [Related]
57. Radioprotector WR-2721 and mitigating peptidoglycan synergistically promote mouse survival through the amelioration of intestinal and bone marrow damage. Liu W; Chen Q; Wu S; Xia X; Wu A; Cui F; Gu YP; Zhang X; Cao J J Radiat Res; 2015 Mar; 56(2):278-86. PubMed ID: 25617317 [TBL] [Abstract][Full Text] [Related]
58. Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). Yazbeck VY; Villaruz L; Haley M; Socinski MA Cancer J; 2013; 19(3):231-7. PubMed ID: 23708070 [TBL] [Abstract][Full Text] [Related]
59. ROS-scavenger and radioprotective efficacy of the new PrC-210 aminothiol. Peebles DD; Soref CM; Copp RR; Thunberg AL; Fahl WE Radiat Res; 2012 Jul; 178(1):57-68. PubMed ID: 22702647 [TBL] [Abstract][Full Text] [Related]
60. Magnetic resonance imaging of organic contrast agents in mice: capturing the whole-body redox landscape. Davis RM; Matsumoto S; Bernardo M; Sowers A; Matsumoto K; Krishna MC; Mitchell JB Free Radic Biol Med; 2011 Feb; 50(3):459-68. PubMed ID: 21130158 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]